Stool testing for the early detection of pancreatic cancer: rationale and current evidence.
The development of effective tools for the early detection of pancreatic cancer, or its precursors, in high-risk subjects could play a key role in reducing the burden of this disease, which is the most lethal among solid gastrointestinal tumors. Given the poor accessibility of the pancreas due to its anatomic site, and given the limitations of imaging modalities, biomarker screening might be a promising diagnostic option. This review focuses on the rationale of using stool markers for the early detection of pancreatic cancer, and systematically summarizes current evidence. Despite several potential advantages of stool testing for pancreatic cancer and its biological plausibility, only six studies investigating two genetic markers in stool (the K-ras and the p53 gene) could be identified. Even though these studies were limited in size and could hardly approximate the screening setting, both markers appear to lack sensitivity and, in particular, specificity. The investigation of further marker candidates (e.g., epigenetic markers) in adequately designed studies represents an important next step to explore the potential of stool testing for pancreatic cancer. Pertinent studies could greatly benefit from recent methodological advances gained in connection with stool testing for colorectal cancer.
Haug
Ulrike
U
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Bergheimer Street 20, Heidelberg 69115, Germany. u.haug@dkfz.de
Wente
Moritz N
MN
Seiler
Christoph M
CM
Jesenofsky
Ralf
R
Jesnowski
Ralf
R
Brenner
Hermann
H
D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D055088:Early Detection of Cancer; D005243:Feces; D006801:Humans; D008403:Mass Screening; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism
D014408:Biomarkers, Tumor